At the American Association for Cancer Research (AACR) Annual Meeting 2024, significant findings from the Phase I/II PETRA trial, led by researchers at The University of Texas MD Anderson Cancer Center, were presented. The trial focused on evaluating the first-in-class PARP1-selective inhibitor, saruparib, in patients with homologous recombination repair (HRR)-deficient breast cancers.
Key Findings:
Promising Efficacy: Saruparib demonstrated promising early efficacy, with an objective response rate of 48.8% and a median progression-free survival of 9.1 months among 31 patients with advanced breast cancers harboring HRR deficiency mutations.
Favorable Safety ...
